Bragar Eagel & Squire, P.C. Is Investigating Corcept, Rollins, Target, and TG Therapeutics and Encourages Investors to Contact the Firm

NEW YORK, July 10, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Corcept Therapeutics, Inc. (NASDAQ:CORT ), Rollins, Inc. (NYSE:ROL ), Target Corporation (NYSE:TGT ), and TG Therapeutics, Inc. (NASDAQ:TGTX ). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided. Corcept Therapeutics, Inc. (NASDAQ:CORT ) On December 8, 2021, Corcept disclosed in a filing with the U.S. Securities and Exchange Commission that "[o]n November 15, 2021, the Company received a records subpoena from the U.S. Attorney's Office for the District of New Jersey (the ‘NJ USAO') pursuant to Section 248 of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) seeking information relating to the sale and promotion of Korlym, Corcept's relationships with and payments to health care professionals who can prescribe or recommend Korlym and prior authorizations and reimbursement for Korlym." Corcept further disclosed that "[t]he NJ USAO has informed Corcept that it is investigating whether any criminal or civil violations by Corcept occurred in connection with the matters referenced in the subpoena." On this news, Corcept's stock price fell $3.71 per share, or 16.91%, to close at $18.23 per share on December 8, 2021. For more information on the Corcept investigation go to: https://bespc.com/cases/CORT Rollins, Inc. (NYSE:ROL ) On October 28, 2020, Rollins disclosed a ... Full story available on Benzinga.com